Inclusion Criteria:  The participant has type 1 diabetes as defined by WHO for at least 1 year The participant is 18 years of age or older The participant will have been on an insulin pump for at least 6 months with good knowledge of insulin self-adjustment The participant is treated with one of the rapid acting or ultra-rapid acting insulin analogues (Insulin Aspart, faster acting insulin Aspart, Insulin Lispro, ultra-rapid Lispro insulin or Insulin Glulisine) HbA1c ≥8.0% (64 mmol/mol) based on analysis from local laboratory The participant is willing to wear closed-loop devices The participant is willing to follow study specific instructions Female participants of child bearing age should using effective contraception and must have a negative urine-HCG pregnancy test at screening.  Exclusion Criteria:  Any physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results Known or suspected allergy against insulin Total daily insulin dose > 2 IU/kg/day Use of a closed-loop system within the past 30 days Participant is pregnant or breast feeding or planning pregnancy within next 12 months Severe visual impairment Severe hearing impairment Lack of reliable telephone facility for contact Participant not proficient in English